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Drawing on insights from feminist and Science and Technology Studies writing on care and vulnerability,
this paper will critically explore conceptualisations of responsibility, care and vulnerability in relation to
contemporary approaches to Responsible Innovation (RI). Drawing on examples of some of the social and
ethical challenges of precision medicine, we highlight the on-going, distributed and complex nature of
innovation and responsibilities in relation to markets, patient and carer experience and data practices
associated with these new technologies to highlight some of the limits of RI. We end by reﬂecting on the
implications of our analysis for the social and ethical challenges of precision medicine and RI more
generally.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Public and policy concerns about the risks of emergent tech-
nologies have lead to the development of a range of policy tools to
guide the innovation process. One such approach which has gained
popularity in recent years is Responsible Innovation (RI). A variety
of frameworks and initiatives have emerged under this broad
banner. For example, public research funding organisations such as
the UK's Engineering and Physical Sciences Research Council have
developed a range of RI agendas aimed at the research community.
Typically these are focused on encouraging, supporting or in some
cases requiring researchers to be reﬂexive about their research
practices, to consider the implications and applications of their
actions, and to involve and engage with publics and their concerns
through the research process (see for example [W1]. Social scien-
tists have been actively involved in developing and embedding
these initiatives in Higher Education and research funding in-
stitutions across Europe and the USA. Their work has focused on
helping researchers and innovators to assess and respond to a
plethora of evidence concerning the extent to which emergent
innovation meet societies' needs, and fostering appropriate modes
of engagement for stakeholders to help to anticipate and mitigate
the risks which might arise from the development of ther Ltd. This is an open access articletechnology [1e3]. In one of the most inﬂuential contributions on
the subject, Von Schomberg describes Responsible Research and
Innovation as a.
transparent, interactive process by which societal actors and
innovators become mutually responsive to each other with a view
to the (ethical) acceptability, sustainability and societal desirability
of the innovation process and its marketable products (in order to
allow a proper embedding of scientiﬁc and technological advances
in our society) [2].
RI has had particular currency in research and policy commu-
nities concerned with environmental and bio-technologies such as
synthetic biology, nanotechnology and geoengineering, especially
those associated with large EU and/or national research funding
programmes. A range of detailed models or frameworks for RI have
been proposed in order to achieve the dual goals of more ethical
and engaged research and innovation. For example, Fisher [4] has
developed a ‘decision model’ for the purpose of encouraging re-
searchers' reﬂection on the process of innovation based on the
principle of ‘midstream modulation’. The model can be embedded
into the research process in the form of an interview protocol
which functioned as a feedback mechanism, thus ‘creating a more
self-critical environment for knowledge production, and perturb-
ing the system in research-tolerable ways’ [4].
Building on this, Owen et al. have suggested a framework for RI
based on three dimensions: anticipation of potential impacts;
reﬂection on underlying purposes; inclusive opening up of reﬂec-
tion to broad, collective deliberation [3]. This, they suggest, needs tounder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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learning’ (755) [3]. For Owen et al. [3], rather than researchers
following rules it is necessary to emphasise values of care and
responsiveness. They stress the importance of collective future-
oriented care, characterised by anticipation (rather than predic-
tion) of potential problems and the intertwining of the futures of all
relevant stakeholders broadly deﬁned. In this framework, more
responsive processes of innovation not only prevent risks and
promote safe and effective technologies, they also bring brings jobs,
prosperity and social beneﬁts.
The broad consensus around the beneﬁts of these approaches to
research and funding processes notwithstanding, a range of critical
concerns have been raised about the limits and problems of the
notions of responsibility and innovation which underpin these
kinds of approaches to RI.
In one recent article, de Saille and Medvecky [5] have argued,
that RI offers a limited view of how we might exercise our re-
sponsibilities for the future via innovation. They note that RI tends
to equate innovation with positive economic growth, but that this
does not tackle the problematic consequences of economic growth
for society or the environment:
once RI is unpacked to reveal the moral underpinnings of its
original formulation e in which ‘responsible’ has a caretaker
mission to ensure that new technologies are both environmentally
safe and sustainable (the requirements for which are not neces-
sarily commensurate) e the relationship between RI and economic
growth can become very unhappy indeed (5e6) [5].
In their exploration of what might constitute ‘responsible
stagnation’, de Saille and Medvecky [5] consider how RI might
involve less, not more, technological innovations, and focus on the
kinds of social innovations that could be more ‘responsible’ by
virtue of their judicious slowing down of the innovation and proﬁt
cycles, e.g. the case of Patagonia, which sells outdoor equipment
using re-cycled materials using a business model with a modest
price and proﬁt margin.
Van Oudheusden [6] has also argued that responsible innova-
tion agendas do not tend to engage with how innovations are
produced or marketed and what kinds of social and political con-
sequences this brings, because they focus on the ethical rather than
the economic. The operationalisation of RI frameworks in activities
such as Technology Assessment, do not tend to address the pro-
cesses through which power is distributed and contested: ‘Rather,
these frameworks largely ignore questions about the politics in and
of deliberation, the authoritative allocation of values, and the
institutional uptake of deliberative engagements’ (67) [6]. Di Guilio
et al. [7] have also drawn attention to the need to engage with
marginalised perspectives in RI and to move from frameworks and
methodologies based around ‘idealised rational forms of delibera-
tion’ to include more marginalised perspectives which recognise
vulnerability.
Drawing on a rich vein of feminist scholarship, other Science
and Technology Studies scholars have further troubled the idea of
RI as matter of collective care for the future as proposed by Owen
et al. [3]. Groves points out, the emphasis in much RI on consulting
and engaging with a wide array of stakeholders stops short of
critical engagement with the ways in which society is organised
around ‘living the future’ via imaginaries which drive particular
practices of investment and growth. Instead Groves suggests we
need ‘a new ethos for living with technology’ (13) [8] and a more
thorough consideration of how subjects andmaterial arrangements
interact [9].
These critical interventions suggest that contemporary RI
agendas might be based on rather limited conceptualisation of re-
sponsibility, innovation and care for the future. Although these
approaches champion researchers', innovators' and funders'responsibilities to consider the consequences of their work for
society, there is little scope for these and other involved actors to
engage with or intervene in the wider systems of distribution or
exchange of any products or technologies which might arise from
their efforts. Although there is clearly an openness to mitigating
risks or slowing the innovation process, the emphasis in much of RI
remains on investment in technological (as opposed to social)
innovation and on innovation rather than ethical forms of inaction.
And efforts at deliberation or public engagement conceived around
‘stakeholders’ and consensus limit the kinds of voices and consid-
erations of responsibility and innovation.
In order to further our understanding of the limits of contem-
porary approaches to RI, we can also turn to feminist and STS
writings on innovation, care and vulnerability.
Following Puig de la Bellacasa [10], in a recent special issue on
care and technology, Martin et al. [11] argued that to fully engage
with what care might mean in relation to science and technology
we need to focus on who is asked to or able to care, for what kinds
of things and futures and to open up consideration of the kinds of
social actors, things and contexts we engage with as part of these
processes. So rather than thinking primarily in terms of stake-
holders and technological innovations, we need to consider those
who might be absent or marginalised from engagement processes
or markets through which technologies might develop, and care
about these markets and other kinds of things and processes they
involve or interact with too. Feminist STS writing also stresses the
importance of a careful consideration of the ‘dark side’ of care:
Care is a selective mode of attention: it circumscribes and
cherishes some things, lives, or phenomena as its objects. In the
process, it excludes others. Practices of care are always shot
throughwith asymmetrical power relations: who has the power
to care? Who has the power to deﬁne what counts as care and
how it should be administered? Care can render a receiver
powerless or otherwise limit their power. It can set up condi-
tions of indebtedness or obligation. It can also sediment these
asymmetries by putting recipients in situations where they
cannot reciprocate. Care organizes, classiﬁes, and disciplines
bodies (625) [11].
This warns us to take care around ideas such as ‘care for the
future’ and its articulation in RI agendas, drawing attention to the
dangers and damage of particular ways of caring and those it di-
minishes. As STS researchers who have become enrolled in
responsible innovation agendas have also argued, care can all too
readily become a matter of ‘observation’ at a distance - a perfor-
mance of concern - rather than critical interventionwhich reshapes
technological innovation [12]. Martin et al. conclude: ‘The lesson
here is that an ethic of response-ability, and thus an ethic of care,
cannot be institutionalized or standardized’ (641) [11] as the pro-
cess of standardisation or institutionalisation inevitably involves
acts of caring less or carelessness, problematising RI which seeks to
embed ‘care for the future’ in institutional processes.
These arguments are also developed in a rich and diverse
literature on vulnerabilities, which has grown from feminist work
on the ethics of care [13] and STS analyses of innovation [7] [14].
The starting point for many feminist analyses of vulnerability is that
the human body and subject is inherently vulnerable, and in need
of care [15e17]. Vulnerability, or the human capacity to suffer,
therefore brings with it certain kinds of moral and political obli-
gations to intervene, innovate, care. This reminds us to consider
how innovations, be they technological or social, address vulnera-
bilities, meet material, bodily and psychological needs; how they
prevent exploitation; and how they protect us from hazards.
However, thinking with vulnerability also focuses attention on the
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vites us to consider what kinds of vulnerabilities might be pro-
duced by innovations, once more extending the ‘matters of care’
that RI typically focuses on e risks, beneﬁts and impacts - to
consider how innovations impinge on the psychosocial and exis-
tential as well as the values and dynamics of the collective.
From an STS perspective, Hommels et al. [14] emphasises the
‘natural’, social and the technical dimensions of vulnerability,
casting vulnerability as an ‘emergent property of systems’ which is
neither intrinsically positive or negative (6). These scholars are
particularly interested in the vulnerabilities engendered by de-
pendency on complex technological systems, highlighting the
problems of ‘rule following’ in engendering a lack of care or
responsiveness in relation to hazards as they develop. They also
explore the creative possibilities of vulnerability e the impetus to
learn and innovate in ﬂexible and open ways, including via
‘breaking the rules’ imposed to protect against vulnerability and the
beneﬁts of being sensitive to a diversity of perspectives shaped by
vulnerability in being reﬂexive about innovation priorities [7]. Once
more this asks us to engage with a wider repertoire of caring
practices and responsibilities than RI agendas might suggest. It also
raises the possibility that innovations and indeed frameworks for RI
might engender carelessness e i.e. dependency, insensitivity and a
lack of reﬂexivity - despite the best intentions of their innovators.
Together these critical approaches to responsible innovation,
care and vulnerability raise three particular challenges to frame-
works for responsible innovation which emphasise responsiveness
and collective care for the future.
Firstl, they suggest the need to engage more fully with the po-
wer and knowledge politics involved in the innovation process: or
as van Oudheusden [6] put it, economics rather than ethics. This
requires that we consider the role of the market in addressing and
generating vulnerabilities and what this means for responsible
innovation. We also need to consider how the market provides
technological solutions to want and disease via innovations sold as
commodities and how these processes can generate vulnerabilities
because they distribute resources unevenly on the basis of ability to
consume not on the basis of need [5,18].
Secondly, these literature suggests the need to grapple with the
problems that arise when innovations designed to empower or
enable individuals or groups labelled as vulnerable or in need of
care are experienced by individuals as disempowering, or pater-
nalistic [17]. For example, as Brown's work [19] suggests, technol-
ogies that are focused on ‘giving back’ autonomy to vulnerable
individuals tend to focus attention on ‘ﬁxing’ individuals, rather
than the structures that generate their vulnerability. We need to
consider what this kind of disconnection between the intentions of
innovators and the experiences of users means for agendas for
responsible innovation.
A third area for further consideration is the vulnerability of in-
novations and the technological systems they are part of and how
this impacts on users and innovators alike. Innovations can also
produce dependencies which, in turn, produce vulnerabilities
when innovations or markets fail [20]. Users can be rendered
vulnerable when they can no longer access the technologies, and
technologies and market are also rendered vulnerable when the
infrastructure they are part of fails. Similarly, innovators, producers
and providers are vulnerable to a decline in uptake or failing in-
frastructures and to the lack of ﬂexibility in rule-bound systems
[14]. This raises the question of who cares and how care is
distributed across networks of engineers, markets and innovations
as well as their users [21]. In the landscape of new technologies it is
especially important to consider the vulnerabilities associated with
the data that many of these technologies and the innovators and
users they are connected to generate, distribute and utilise [22,23].In the remainder of this paper we explore the complexities of
responsibility, innovation, care and vulnerability by reﬂecting on
the social and ethical context of precision medicine in an effort to
further elaborate the limits of responsible innovation. Precision
medicine is an exemplar of the kind of multi-layered processes of
technological and social innovation, and the complex regulatory
andmarket systems inwhich innovators are currently working. It is
also an example replete with numerous vulnerable actors, and
complex dynamics of care. As such it provides fertile ground for
thinking about the conceptual and practical limits of RI. Here we
seek tomove beyond thinking of responsibility and innovation only
in relation to technological innovations, or innovations which
generate economic growth, at the same time as reﬂecting on the
complexities and paradoxes of care involved in innovation prac-
tices. We then turn to explore complexities of vulnerabilities
associated with markets, patient and carer experiences and data
networks. Note that our purpose is not to present a case study of
precision medicine or systematic analysis of RI frameworks; nor do
we seek to develop a reﬁned framework for RI. Instead we are of-
fering a critical exploration of responsibility and innovation via
some illustrative examples of the complexities of precision medi-
cine in an effort to better understand the limits of contemporary RI
agendas.
2. Precision medicine
Recent developments in high throughput genomic sequencing,
coupled with rapid advances in understanding of the genomic basis
of diseases like cancer have transformed biomedical research. In
countries like the UK and USA high proﬁle national initiatives have
been launched to harness the power of patient data to identify
genes involved in disease and develop targeted treatments and
therapies (see for example [W2, W3]). These initiatives seek to
build on the paradigm of personalised or targeted medicine in
ﬁelds such as oncology where some cancer patients, for example
breast cancer patients with HER2 positive or oestrogen receptor
positive cancers are offered targeted treatments as part of their
care. A growing list of drugs have been developed, particularly for
blood, breast, colorectal, kidney, lung and skin cancers (see [W4]).
Some of these drugs are available to patients in publically funded
health care systems, but costs are high and beneﬁts difﬁcult to
quantify without controversy, leading to high proﬁle disputes be-
tween some regulators and pharmaceutical companies such as the
recent dispute between the UK's National Institute for Health and
Care Excellence which approves medicines for NHS use, and Roche,
the manufacturer of Kadcyla, a treatment which costs approxi-
mately £90,000 per patient (see [W5]). Precision medicine also has
implications for biomarker monitoring for patients, including those
at risk of cancer developing or returning. This can involve the
identiﬁcation of new subtypes of cancer which may be treated
differently. It can also apply to monitoring the progression of dis-
ease. A particular promise of these approaches is that they could
help to minimise the use of invasive tissue biopsies, using blood
tests instead.
For themost part, precisionmedicine is a research initiative, and
its impact on routine diagnosis and treatment in the clinic has been
relatively modest. Patients are increasingly involved in providing
data for these programmes via large scale clinical trials and studies
which produce, link and share increasingly detailed clinical, social
and biological patient data. Although the collection and use of this
data has caused concerns and anxieties around privacy and
exploitation [24], participation is key: precision medicine has also
enrolled patients as participants, as described in the ‘P4’ paradigm
of precision medicine as ‘predictive, preventative, personalised and
participatory’. Here patients and publics are not only providing
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tors on trials, treatments and tests [25].
2.1. What kinds of innovation are involved in precision medicine?
Precision medicine is typically framed as a set of technological
innovations which are responsive to the needs of the population in
away which traditional forms of medicine have not been. To realise
these beneﬁts, emphasis is placed on ‘scaling up’ tests and treat-
ments via a range of state and industry programmes and in-
vestments. For example, the Precision Medicine Catapult, aims to
‘make the UK a world-leading centre for precision medicine’ [W6]
by accelerating precision medicine so that the advances of
research and innovation can be more widely available. Stratiﬁed
Medicine Scotland [W7] is a ‘platform for collaboration linking
Scotland's expertise, data assets and delivery infrastructure to
accelerate the real world adoption of PrecisionMedicine’. Emphasis
is placed on innovations in the life sciences, genomics and data
analytics.
These characterisations of innovation in precision medicine also
involve discussion of the ethical or responsible innovation of tests
and treatments, in particular the need to accelerate developments
so that they can be accessed bymore patients (e.g. Ref. [26]) and the
need to store and share data responsibly (e.g. Ref. [27]). RI agendas
for precisionmedicine focus on these kinds of issues through public
deliberation and engagement around what kinds of data ought to
be collected and shared for the public good (e.g. [W9]).
When we broaden our conceptualisation of innovation beyond
these core technologies, we nevertheless ﬁnd that a range of other
issues around how to care for participants, data, technologies, cit-
izens and healthcare processes and practitioners arise. Precision
medicine involves innovations in the role of patients, publics, sci-
entists and healthcare professionals, as well as in the stewardship
of data. As Keating and Cambrosio's [28] analysis of contemporary
oncology suggests, it is part of a platform of technological in-
novations which have transformed the nature and scope of clinical
trials and studies and given them a prominent place in the in-
stitutions of healthcare, so much so that for patients experiencing
diseases like cancer, it is becoming more of an expectation rather
than an exception for them to be part of a trial or study during their
treatment. Precision medicine requires this industry of trialists and
research participants in order to be a successful innovation. These
‘upscaled’ trials are an innovation in their own right and they bring
with them innovations in terms of the ﬂow of information, consent
procedures, and professional practices, e.g. multidisciplinary team
meetings and procedures for removing, transporting and storing
tissue. In addition, in order to recruit patients to these studies and
trials, healthcare organisations are developing increasingly so-
phisticated public relations and media campaigns, often in part-
nership with patient organisations as co-producers. This
constitutes an innovation in ways of working with patients or
interested publics but it also constitutes an innovation in the nature
of patienthood.
Through these broader social and technical innovations, patient,
public and practitioner responsibilities are developing and chang-
ing, as are the practices of care with which they are involved. Pa-
tients are no longer simply responsible for their own health but for
future patients e be they family members or wider groups of
strangers sharing a similar genotype. Patients and associated pub-
lics have acquired responsibilities as co-innovators rather than as
passive recipients of these technologies. And healthcare managers,
scientists and other actors involved in the delivery of precision
medicine have taken on responsibilities for transforming the health
service to make precision medicine workable. This might involve
reworking or restaging information, data or research protocols, aswell as recycling of old materials and infrastructures, including, for
example, biological samples and health records, albeit with the
innovation of new ways of seeking and securing consent for such
processes. Deliberation is also a new kind of responsibility which
comes alongside technologies like precision medicine.
Looking at innovation across this suite of interlinked activities
suggests that responsibilities for professionals, participants, and
publics are proliferating in the precision medicine era, but a nar-
rower focus on precision medicine as a form of technological
innovation which in turn places emphasis on responsibilities for
risk mitigation via engagement leaves little space to consider the
implications of these changes and the kinds of burdens, re-
sponsibilities and unintended consequences they might bring to an
array of involved and marginalised actors. Instead we need to look
at how these developments are reconﬁguring practices of care
more broadly: who cares, what do they care about, and what kinds
of carelessness does this engender?
2.2. What kinds of care does precision medicine involve and for
whom?
Fostering awareness of the kinds of individuals, institutions and
things that innovations allow to ﬂourish is, of course, a laudable
aim of RI. But it is also important to ask who does this work of
caring for the future, and who experiences or is likely to experience
these ways of caring as positive or negative? We already know that
care is often devalued work, performed by the socially marginal-
ised. Does this happen in the case of responsibility-work conducted
in relation to precision medicine? Are particular kinds of scientiﬁc
and healthcare workers, or indeed volunteers, doing this work
more than others, and is this work performative, i.e. happening at a
distance from the main innovation process, with little profound
effect on how it unfolds?
There are reasons to think that this might be the case, when we
look at the kinds of public caring about the future of healthcare that
particular actors are performing in relation to precision medicine:
former patients, journalists and scientiﬁc commentators are
involved in a wide array of public discussions about these impor-
tant innovations, fostering debate and critical dialogue with inter-
ested patients and their carers and families. Caring in these ways is
a time-consuming business for some of these actors, who can
develop a portfolio of commitments to various involvement ini-
tiatives and events. This inevitably means that certain kinds of
people become more involved than others e participants are more
likely to have reserves of social and ﬁnancial capital to draw upon
than others who have less time and feel that they have less to
contribute. This then shapes the kinds of cares being articulated
through these processes, as well as creating a group of more mar-
ginalised actors who might be cared about in their absence, for
example people living in poverty. It also generates a need to care for
the carers, who devote their time and energy to these processes. For
example the nurses and administrators involved in engagement
activities perform the bulk of this kind of emotional labour ontop of
an increasing patient case load, and there is a need to distribute and
recognise this work properly. As Sinding and colleagues [29] have
also documented, tensions and inequalities that comewith patients
taking on responsibilities to represent the views of other patients in
consultation processes, in particular, ‘initiatives that endorse and
promote ‘the involved patient’ can function to exacerbate health
care and social disparities' (400).
At the same time, this public engagement care work does not
capture the messy kinds of care work required of research partic-
ipants in precision medicine. As Day et al. (2016) [30] have recently
noted, precision medicine intensiﬁes the navigation labour for
patients and their carers, due to the increasing levels of work. There
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side-effects, ensuring transport is available, waiting around whilst
treatments are administered, keeping awatchful eye on how things
progress. This is the emotional, often dirty side of care-work, that
tends to fall to women and other low paid or unpaid kinds of
workers [31,32], but it does not often ﬁgure in the kinds of ‘col-
lective care for the future’ associated with frameworks for
responsible innovation.
Another feature of care work also requires some consideration
here: namely its potentially oppressive qualities: to be ‘in care’ or
‘in need of care’ can restrict freedoms. Surveillance can be posi-
tioned as a form of care, as can restrictions on diet or movement,
but these practices might not be experienced as caring. Might then
the kinds of regimes associated with participation in precision
medicine be experienced as restrictive by some kinds of patients or
participants? Could taking up the opportunity for better care via
new tests or treatments, or participating in studies or trials asso-
ciated with precision medicine, actually be experienced as less than
care, particularly if the person concerned is participating out of a
sense of obligation, or compliance, for example with the wishes of
family? This suggests the need to reconsider what kind of collective
care RI demands and of whom, as well as its ‘dark side’.
2.3. An exploration of vulnerabilities associated with precision
medicine
Precision medicine is often billed as a surgical strike on faulty
genes or other kinds of biological functions gone awry e or as a
means of protecting the body from these vulnerabilities. It never-
theless introduces a complexity of vulnerabilities through these
processes, given the dynamism of the social and biological ar-
rangements of which it is a part. In this section we explore some
key features of this complexity of vulnerability and what it means
for RI.
2.3.1. Markets
We focus ﬁrst on the vulnerabilities addressed and introduced
by the market in precision medicine: a political economic
arrangement which has profound and particular implications for
how the beneﬁts of precision medicine are distributed, but which is
not fully considered in RI frameworks which privilege the ethical
over the economic [6]. Precision medicine is often presented as an
important stimulus for economic growth in particular national
contexts. However, patients' access to these treatments is also
limited by affordability [33]. The state is investing research re-
sources and in some cases public infrastructure (e.g. UK National
Health Service) in an effort to stimulate this market, but is also
regulating the technologies to ensure that public money is spent
wisely e this means that not all patients are able to access these
treatments funded by the state [34,35]. There is a pathogenic
vulnerability [14] here: innovation which beneﬁts the economy
may be stimulated by the market system but their value in terms of
patient beneﬁt is not being realised across the nation. Reduced
access to these treatments renders already vulnerable patients,
particularly those with limited resources, more vulnerable as
compared with wealthier others who are able to beneﬁt from these
treatments. Within this kind of market system, the innovation
process means that only certain futures are cared for.
As Day et al. [30] have also noted in their study of precision
medicine in breast cancer, the processes of specialisation stimulate
outsourcing of particular aspects of care work to external parties,
contributing to the marketisation of public health systems like the
UK NHS. This has wider ramiﬁcations for patient care across the
health system, as private providers take on an increasingly prom-
inent role in care. They note:the practices of stratiﬁedmedicine have an elective afﬁnity with
both the outsourcing of particular support services and occu-
pational specialisation, suggesting that an indirect relationship
exists between developments in these different forms of strat-
iﬁcation. As far as clinicians and patients were concerned, the
spaces for holistic care have become more and more restricted.
(10) [30].
Thinking through responsibilities and innovation in precision
medicine requires that we grapplewith how themarket operates as
well as the implications of these developments for social justice
and equity. However, there is little scope for engaging with these
issues within RI frameworks which conceptualise innovations, re-
sponsibilities, care and futures primarily in terms of technology,
ethics and stakeholder engagement. RI frameworks which focus on
intervening in the activities of a limited range of innovators - such
as scientists and engineers working in universities - are not well
positioned to engage with the market in these ways, not least
because of theway responsibilities for themarket are so ambiguous
and diffuse. There is also the challenge in giving voice to people's
experiences of new technologies when they do not conform to the
promissory agendas of market and state providers, especially when
they contradict their stated aims and beneﬁts. A thoroughgoing
analysis of responsibility and innovation also require that we
engage seriouslywith the ‘dark sides’ of markets and their potential
undermining of public systems and resources.2.3.2. Experiencing precision medicine
We also need to consider the vulnerabilities that patients and
carers experience when encountering precision medicine, partic-
ularly in relation to the emphasis on individualisation in precision
medicine. As patients negotiate the ‘political economy of hope’ [36]
around treatment, their expectations are raised and sometimes
dashed as their treatment progresses, including when they seek out
access to experimental medicines through trials, sometimes far
from home. Day et al. [30] note that patients in their study expe-
rienced a less rather than a more personalised service because they
were often on the move between different kinds of specialists and
care providers. More generally, other studies suggest that patients
or people who have experienced diseases like cancer can also be
rendered vulnerable by discourses of empowerment or survivor-
ship, which emphasise the need to be active, informed and
participating in the latest tests, treatments and public discourses of
triumph and solidarity [37,38]. Although images of suffering can be
a force for social solidarity and concern [39], they can also be
experienced as alienating for those in the same situation, who are
unable or do not wish to share in this way [40]. These patients are
vulnerable to feelings of being ‘out of place’ as well as experiencing
stigma and social opprobrium should they not wish to participate
in heroic, experimental or tailored treatments.
Precision medicine is very much focused upon offering patients
choices around their treatment to tailor their treatment more
effectively. This is part of a wider menu of choices which patients
navigate in the course of their treatment: choice about what trials
or studies to participate in, what hospital to attend, what consul-
tant to see, what treatments to take, what information to access,
what support groups to attend, what data or tissue to share or
donate, what information to discover. Choice is often held up as a
means by which to protect against vulnerabilities [41]. However,
choice, like care and markets, has its dark side. Choice can be
experienced as an onslaught of options and opportunities, which
can render patients and their families feeling vulnerable, despite
the best intentions of care providers and the scientists they work
with [42]. Too much of an emphasis or reliance on informed choice
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lead to problems with over-diagnosis and a transfer of re-
sponsibility from physicians to patients in away that causes anxiety
and feelings of guilt or regret for patients experiencing the ‘diag-
nostic cascade’ which follows [43]. It is also well documented that
an individual's capacity to choose is limited by a range of cognitive,
health and psychosocial factors, so choice does not provide a ‘level
playing ﬁeld’ in the battle for health [44]. The tensions around
choice also extend to the period before or after treatment e when
individuals are ‘at risk’ or ‘in remission’. How to choose the best
lifestyle and monitoring regime to ensure continued health? Hal-
lowell et al. [45] have amply demonstrated the anxieties and re-
sponsibilities towards family members which these kinds of tests
and information can generate, as individuals make choices about
when to know and when to share information of relevance. This
also applies to the disclosure of ‘incidental ﬁndings’ generated by
precision medicine, whereby patients have to make complex de-
cisions about what they may want to know about their or a
members of their families' risks of developing other diseases in the
future at a point at which they are particularly vulnerable because
they are suffering from the effects of their disease and treatments
[46]. Here the beneﬁts patients might derive from information
about their health is potentially undercut by the problems of
providing information which is upsetting or difﬁcult to manage
within the family, putting secure identities and relationships at
risk.
Experiences of precision medicine are diverse, unpredictable
and contradictory; they are part of an ongoing and dynamic process
of distributing responsibilities, sometimes in uncomfortable and
unwelcome ways. Greater choice can be experienced as a burden
rather than a beneﬁt. Yet there is very little space to consider and
explore these complex and often highly personal decisions and
experiences within contemporary agendas for responsible inno-
vation focused on ‘collective care for the future’. Although emphasis
is placed on inclusivity in these deliberations, there are numerous
challenges in enabling individuals to appreciate or even voice
feelings and concerns about their responsibilities for care, treat-
ment, diagnosis and research in frameworks designed to address
responsibilities at this meta-level. There is also a lack of scope for
critically reﬂecting on the wider issue of how being involved in
deliberation is itself a kind of responsibility which is differentially
distributed and rewarded.
2.3.3. Data
There is an extensive literature on how to ensure the security of
personal and health data in genomic and biobank research [47].
There is also considerable public concern about the sharing of
personal health data, especially with insurance providers and other
commercial organisations, as the debacle over the recently closed
UK government's Care. data initiative demonstrates [48]. However,
there are powerful and concurrent drivers of health and social data
integration and sharing, which concerns around protecting indi-
vidual privacy are unlikely to quash: scientiﬁc, public health and
commercial organisations are heavily invested in capitalising on
the enormous wealth of data which could be used to develop new
health interventions and treatments in the public and patients'
interests. The UK's 100,000 Genomes project [W9], which will
harness patient records and genetic information on cancer and rare
diseases to generate targeted treatments, is an example of this kind
of initiative in precision medicine. This involves a collaboration
between the UKNHS and Illumina, a private company providing the
high through put sequencing technologies required to analyse this
data, requiring extensive revisions to participating institutions'
laboratory, data and information management practices to enable
the data to be collected and shared in timely fashion. This initiativeis rightly concerned with public engagement in order to secure
patient participation and trust in its practices. As part of this a range
of public education and consultations activities are embedded in
the project, activities which mirror the wider emphasis on public
consultation on data security and consent processes for partici-
pants (as highlighted in the Caldicott review [W10]).
Although there is a clear engagement with responsibilities here,
vulnerability is being constituted in a limited manner as belonging
to individual patients or research participants who need to be
protected from inappropriate use of their data by a range of insti-
tutional processes of consultation, engagement, involvement, pro-
tocols and procedures. Framing vulnerabilities in this narrow way
places considerable reliance on patients or research participants
taking the ultimate responsibility for their choices through the
informed consent process. But as Dijck [22] argues, the lack of
transparency around how data is used means this consent is not
always well informed. Narrow framings of vulnerabilities as a
matter of informed consent for particular uses of individual health
data also fail to take account of all of the other kinds of personal
data and processes of collecting and proﬁting from that data which
might evolve alongside this initiative. As recent controversy over
the ownership of a database of the DNA of Sardinian residents
reveal, even when private companies are not initially part of
research consortia, they can become involved when the data is sold
on [49]. As Lupton [23] has suggested, as sickness is monetised
patients are often unaware of how their data is being used.
Processes such as informed consent, which are designed to
mitigate particular, largely individual, vulnerabilities, but do not
take account of how vulnerabilities manifest in complex ways, have
the potential to create other kinds of vulnerabilities for collectives
too. In the case of large scale state-market collaborations such as
the 100,000 Genomes Project there is also the vulnerability of the
health service to consider. This is under particular strain due to
population ageing and pressures on public ﬁnances, but new ini-
tiatives such as this project require considerable investment in new
processes and arrangements which go beyond project support to
encompass widespread transformations in the way services are
offered. There is, however, little sustained reﬂection on this
implementation challenge in the public sphere; indeed our
research experiences suggest it can be difﬁcult for senior managers
to articulate these concerns publically because of the need to pro-
mote the beneﬁts of the programme inside and beyond their or-
ganisations. This involves professional, institutional and
organisational vulnerabilities which are not readily addressed in
current efforts to involve stakeholders and anticipate risks, focused
as they are on the business of patient recruitment.
This example illustrates how institutional approaches to man-
aging risks and responsibilities of research and innovation in pre-
cision medicine can frame responsibilities in limited ways and
place considerable burdens on patients and participants in the
process. We suggest that there are parallels here with how RI
frameworks operate, typically in institutional contexts which are
designed as part of planning for public investment in particular
initiatives, suggesting that these initiatives might also take a
limited approach to responsibility and innovation by framing these
developments narrowly in terms of participation in programmes
and projects, and using established tools for addressing this, such as
informed consent processes, for example. As with engagement
activities more generally, this limits RI in that it is not well placed to
capture and engage with the complexities of data practices and the
vulnerabilities they bring, especially when potential participants
are not sufﬁciently aware of or do not feel able to articulate the risks
these technologies might bring.
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How, then, might a better appreciation of the distributed and
ongoing processes of responsibility and innovation, and the polit-
ical and economic dynamics of care and vulnerabilities enable new
insights into how to engender responsible innovation of precision
medicine and other related technologies? In this paper we have
explored how responsibilities, care and vulnerabilities can be
framed in somewhat narrow ways in agendas for RI, and tried to
widen the ﬁeld of consideration by exploring the dynamic features
of socio-political, institutional sociotechnical assemblages in which
these technologies and the people who might use them are
involved via the case of precision medicine. We have outlined the
nexus of technological and social innovations of which precision
medicine is a part, and the reconﬁgured caring responsibilities that
this has involved, particularly for patients and their carers navi-
gating complex care pathways and being involved in deliberation
and consultation exercises. We have also explored how efforts to
mitigate but also moderate the vulnerabilities of the body to dis-
ease via more targeted diagnostics and therapies can magnify other
kinds of private and public vulnerabilities, particularly for in-
dividuals affected by disease, but also for the practitioners and
institutions trying to help them. An important theme in this paper
has been the importance of considering vulnerabilities as rela-
tional, dynamic and inter-connected, and of looking beyond
simplistic approaches to their solution based on novel technologies,
greater choice or institutional procedures. We have argued that it is
important to consider the different kinds of demands, care and
emotional work and choices that patients and practitioners, as well
as families and policy and public actors more generally, must face
when negotiating precision medicine and its possibilities, and how
these practices can mediate, but also exacerbate, particular vul-
nerabilities. These kinds of considerations need to be more effec-
tively woven into policy and institutional discourses and processes,
decisions and practices, in order to minimise vulnerabilities locally
and further aﬁeld.
Exploring vulnerabilities has helped to ﬂesh out the range,
possibilities and pitfalls of collective caring for the future suggested
by RI frameworks with respect to different social groups, techno-
logical entities and spaces/timeframes of care. A vulnerabilities
heuristic places social, technical and biological contingency and
dynamism centre stage and protects against any simplistic forms of
determinism or naive consensus around what constitutes respon-
sible innovation. By attending to how it feels to be sick or to be in
treatment, or worried about potential illness in the future, and
exploring a wider set of institutional and politico-economic ar-
rangements through which these concerns and experiences are
conﬁgured, the lens of vulnerability also allows us to approach
responsiveness with both the individual and the social order in
mind: to ‘care with’ rather than ‘for’ the future [13]. Vulnerability is
also a good heuristic for thinking about the pernicious and unin-
tended consequences of some efforts to respond to vulnerability
and, on the other hand, the positive outcomes which can arise from
individual experiences of vulnerability where these give rise to
efforts to improve social solidarity and social justice.
Thinking with vulnerability also draws our attention to two of
the most overlooked dynamics of the contemporary age e ﬁrst the
limits of choice as a form or a goal of responsiveness, and secondly
the dangers of social control arising from efforts to identify and
intervene in the lives of so-called vulnerable individuals and social
groups. Attending to the limits of these strategies is important for
RI more generally, given the extent to which choice has come to
dominate a range of life strategies in contemporary consumer so-
ciety and persistent challenges of social marginalisation and
inequality for those experiencing poverty, disability anddiscrimination, practices which limit both the possibilities of
technological innovation and the good society.
This suggests that responsible innovation initiatives need to be
more open ended and creative about the ways in which they pro-
voke new ways of thinking about and practicing innovation,
including alternative social innovations which complement or
address other kinds of needs. There is a pressing need to critically
engage with markets and the kinds of choices and responsibilities
they bring, and to exercise caution around involvement and
engagement agendas which create more work for particular kinds
of patients and publics. There is also a need to consider the de-
pendencies and inter-actions between different kinds of in-
novations, both social and technical, and to think about the sorts of
innovations in, for example, healthcare delivery, ﬁnancial models,
data and proﬁt sharing and other infrastructures of care that need
to co-evolve alongside technical innovations to ensure their bene-
ﬁts are widely distributed and shared. At the same time, there is a
need to appreciate the limits of what any kind of responsible
innovation agendamight achieve: it is possible for critical reﬂection
to stimulate other ways of innovating and supporting individuals
and communities affected by ill-health, but RI needs to be part of a
wider programme of social change in order to be successful in this
regard.
Acknowledgements
We gratefully acknowledge the support of the Engineering and
Physical Sciences Research Council who funded research on
Responsible Innovation as part of the Innovation and Knowledge
Centre on Regenerative Therapies and Devices Tranche 2 (Grant
number EP/J017620/1) and would also like to thank the special
issue editors Omar Rosas and Brian Earp, the anonymous referees,
Sarah Cunningham-Burley and colleagues at Edinburgh and Leeds
and colleagues involved in the Social Trends Institute event on
Technology and the Good Society.
References
[1] J. Stilgoe, R. Owen, P. Macnaghten, Developing a framework for responsible
innovation, Res. Policy 42 (9) (2013) 1568e1580.
[2] Rene Von Schomberg, Towards Responsible Research and Innovation in the
Information and Communication Technologies and Security Technologies
Fields, Available at: SSRN 2436399, 2011.
[3] R. Owen, P. Macnaghten, J. Stilgoe, Responsible research and innovation: from
science in society to science for society, with society, Sci. Public Policy 39 (6)
(2012) 751e760.
[4] E. Fisher, Ethnographic invention: probing the capacity of laboratory decisions,
NanoEthics 1 (2) (2007) 155e165.
[5] S. De Saille, F. Medvecky, Innovation for a steady state: a case for responsible
stagnation, Econ. Soc. 45 (1) (2016) 1e23.
[6] M. Van Oudheusden, Where are the politics in responsible innovation? Euro-
pean governance, technology assessments, and beyond, J. Responsible Inno-
vation 1 (1) (2014) 67e86.
[7] G. Di Guilio, C. Groves, M. Monterio, R. Taddi, Communicating through
vulnerability: knowledge politics, inclusion and responsiveness in responsible
research and innovation, J. Responsible Innovation 3 (2) (2016) 92e109.
[8] C. Groves, Horizons of care: from future imaginaries to responsible research and
innovation, Shap. Emerg. Technol. Gov. Innov. Discourse (2013) 185e202.
[9] C. Groves, The political imaginary of care: generic versus singular futures, J. Int.
Political Theory 7 (2) (2011) 165e189.
[10] M. Puig de la Bellacasa, Matters of care in technoscience: assembling
neglected things, Soc. Stud. Sci. 41 (1) (2011) 85e106.
[11] A. Martin, N. Myers, A. Viseu, The politics of care in technoscience, Soc. Stud.
Sci. 45 (5) (2015) 625e641.
[12] A. Viseu, Caring for nanotechnology? Being an integrated social scientist, Soc.
Stud. Sci. 45 (5) (2015) 642e664.
[13] J.C. Tronto, Moral Boundaries: a Political Argument for an Ethic of Care,
Routledge, London, 1993.
[14] A. Hommels, J. Mesman, W.E. Bijker (Eds.), Vulnerability in Technological
Cultures: New Directions in Research and Governance, MIT Press, Cambridge,
M.A, 2014.
[15] M.A. Fineman, A. Grear (Eds.), Vulnerability: Reﬂections on a New Ethical
Foundation Ror Law and Politics, Ashgate, Farnham, 2013.
A. Kerr et al. / Technology in Society 52 (2018) 24e31 31[16] P.S. Anderson, Autonomy, vulnerability and gender, Fem. Theory 4 (2) (2013)
149e164.
[17] C. Mackenzie, W. Rogers, S. Dodds, Vulnerability: New Essays in Ethics and
Feminist Philosophy, Oxford University Press, Oxford, 2014.
[18] S. Coyle, Vulnerability and the liberal order, in: Martha Albertson Fineman,
Anna Grear (Eds.), Vulnerability: Reactions on a New Ethical Foundation for
Law and Politics, vol. 6175, Ashgate Publishing Limited, Surrey, 2013.
[19] Kate Brown, Vulnerability’: handle with care, Ethics Soc. Welf. 5.3 (2011)
313e321.
[20] Morgan Cloud, More than utopia, in: Martha Albertson Fineman, Anna Grear
(Eds.), Vulnerability: Reﬂections on a New Ethical Foundation for Law and
Politics, vol. 7794, Ashgate Publishing Limited, Surrey, 2013.
[21] Michel Callon, Annalivia Lacoste, Defending responsible innovation, Debating
Innov. 1 (1) (2011) 19e27.
[22] J.v. Dijck, Dataﬁction, dataism and dataveillance: Big Data between scientiﬁc
paradigm and secular belief, Surveillance Soc. 12 (2) (2014) pp.197e208.
[23] D. Lupton, The commodiﬁcation of patient opinion: the digital patient expe-
rience economy in the age of big data, Sociol. health & Illn. 36 (6) (2014)
856e869.
[24] Isaac S. Kohane, Ten things we have to do to achieve precision medicine,
Science 349 (6243) (2015) 37e38.
[25] Mauricio Flores, et al., P4 medicine: how systems medicine will transform the
healthcare sector and society, Pers. Med. 10 (6) (2013) 565e576.
[26] Akram Alyass, Michelle Turcotte, David Meyre, From big data analysis to
personalized medicine for all: challenges and opportunities, BMC Med. ge-
nomics 8 (1) (2015) 33.
[27] Samuel J. Aronson, Heidi L. Rehm, Building the foundation for genomics in
precision medicine, Nature 526 (7573) (2015) 336e342.
[28] Peter Keating, Alberto Cambrosio, Cancer on Trial: Oncology as a New Style of
Practice, The University of Chicago Press, 2012.
[29] C. Sinding, P. Miller, P. Hudak, S. Keller-Olaman, J. Sussman, Of time and
troubles: patient involvement and the production of health care disparities,
Health 16 (4) (2012) 400e417.
[30] S. Day, R. Charles Coombes, Louise McGrath-Lone, Claudia Schoenborn,
Helen Ward, Stratiﬁed or Precision Medicine? Cancer Services in the ‘real
World’ of a London Hospital Sociology of Health and Illness Sociology of
Health & Illness Online Only Early View, 2016, http://dx.doi.org/10.1111/1467-
9566.12457.
[31] Arlie Hochschild, The Managed Heart: Commercialization of Human Feeling,
third ed., University of California Press, 2012.
[32] Nicky James, Care¼ organization þ physical labour þ emotional labour, Sociol.
Health & Illn. 14 (4) (1992) 488e509.
[33] Philip Wahlster, Shane Scahill, Christine Y. Lu, Barriers to access and use of
high cost medicines: a review, Health Policy Technol. 4 (3) (2015) 191e214.
[34] H. Dakin, N. Devlin, Y. Feng, N. Rice, P. O'Neill, D. Parkin, The inﬂuence of cost-
effectiveness and other factors on nice decisions, Health Econ. 24 (10) (2015)
1256e1271.
[35] R. Conti, D.L. Veenstra, K. Armstrong, L.J. Lesko, S.D. Grosse, Personalized
medicine and genomics: challenges and opportunities in assessing effective-
ness, cost-effectiveness, and future research priorities, Med. Decis. Mak. 30 (3)
(2010) 328e340.
[36] Carlos Novas, Nikolas Rose, Genetic risk and the birth of the somatic individual
29, Econ. Soc. 485 (2000).
[37] Kirsten Bell, Biomarkers, the molecular gaze and the transformation of cancer
survivorship, 8 Biosocieties 124 (2013).
[38] K. Bell, S. Ristovski-Slijepcevic, 2013 Cancer survivorship: why labels matter,
J. Clin. Oncol. 31 (4) (2013) 409e411.
[39] J.P. Butler, Precarious Life: the Powers of Mourning and Violence, Verso,London, 2006.
[40] G.A. Sulik, Managing biomedical uncertainty: the technoscientiﬁc illness
identity, Sociol. Health & Illn. 31 (7) (2009) 1059e1076.
[41] Annemarie Mol, The Logic of Care: Health and the Problem of Patient Choice,
Routledge, 2008.
[42] C. Sinding, P. Hudak, J. Wiernikowski, J. Aronson, P. Miller, J. Gould,
D. Fitzpatrick-Lewis, I like to be an informed person but…” negotiating re-
sponsibility for treatment decisions in cancer care, Soc. Sci. Med. 71 (6) (2010)
1094e1101.
[43] M. Johansson, K.J. Jørgensen, L. Getz, R. Moynihan, “Informed choice” in a time
of too much medicinedno panacea for ethical difﬁculties, BMJ 353 (2016)
i2230.
[44] Jennifer Moye, Daniel C. Marson, Assessment of decision-making capacity in
older adults: an emerging area of practice and research, Journals Gerontology
Ser. B Psychol. Sci. Soc. Sci. 62 (1) (2007) 3e11.
[45] N. Hallowell, C. Foster, R. Eeles, A. Ardern-Jones, M. Watson, Accommodating
risk: responses to BRCA1/2 genetic testing of women who have had cancer,
Soc. Sci. Med. 59 (3) (2004) 553e565.
[46] Bartha Maria Knoppers, H Zawati Ma'n, Emily S. Kirby, Sampling populations
of humans across the world: ELSI issues, 13 Annu. Rev. Genomics Hum. Genet.
13 (395) (2012).
[47] Daryl Pullman, Holly Etchegary, Katherine Gallagher, Kathleen Hodgkinson,
Montgomery Keough, David Morgan, Catherine Street, Personal privacy, public
beneﬁts, and biobanks: a conjoint analysis of policy priorities and public
perceptions, Genet. Med. 14 (2) (2012) 229e235.
[48] Eric Boiten, Care.data Has Been Scrapped, but Your Health Data Could Still Be
Shared, 2016. July 12 2016 theconversation.com.
[49] S. Kirchgaessner, Ethical Questions Raised in Search for Sardinian Centenar-
ians' Secrets the Guardian, 2016, 12/08/2016.
Web References
[W1] EPSRC, Framework for Responsible Innovation, 2017. https://www.epsrc.ac.
uk/research/framework/. Accessed 24/01/2017.
[W2] National Institutes of Health, All of Us Research Program, https://www.nih.
gov/research-training/allofus-research-program (n.d.) Accessed 24/01/2017.
[W3] Genomics England, NHS Genomic Medicine Centres. https://www.
genomicsengland.co.uk/taking-part/genomic-medicine-centres/, 2015.
Accessed 24/01/2017.
[W4] National Cancer Institute, Targeted Cancer Therapies, 2014. https://www.
cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-
therapies-fact-sheet. Accessed 24/01/2017.
[W5] NICE, Kadcyla Too Costly for Use on the NHS, 2017. https://www.nice.org.uk/
news/article/kadcyla-too-costly-for-use-on-the-nhs. Accessed 24/01/2017.
[W6] Catapult Precision Medicine. https://pm.catapult.org.uk, 2017. Accessed 24/
01/2017.
[W7] Stratiﬁed Medicine Scotland. http://www.stratmed.co.uk, 2017. Accessed 24/
01/2017.
[W8] National Institutes of Health, Participant Engagement and Health Equity
Workshop, 2016. https://www.nih.gov/allofus-research-program/
participant-engagement-health-equity-workshop. Accessed 24/01/2017.
[W9] Genomics England. https://www.genomicsengland.co.uk, 2015. Accessed 24/
01/2017.
[W10] National Data Guardian, National Data Guardian for Health and Care Review
of Data Security, 2016. Consent and Opt-Outs, https://www.gov.uk/
government/uploads/system/uploads/attachment_data/ﬁle/535024/data-
security-review.PDF. Accessed 24/01/2017.
